CA
VCNX

Clearstead Advisors’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Clearstead Advisors’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$1K – 1313
2021
Q1 		$1K Buy
+1
New +$643 ﹤0.01% 1091

Other funds holding VCNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Advisors's VCNX Position: Q2 2021 in Review

Clearstead Advisors sold out of Vaccinex, Inc. Common Stock (VCNX) in Q2 2021, closing a stake of 1 share — an estimated $1K sold.

Clearstead Advisors first reported a position in VCNX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 24 funds tracked by Wall St. Rank hold VCNX as of Q2 2021.

  • Clearstead Advisors reported no remaining Vaccinex, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Clearstead Advisors sold 1 Vaccinex, Inc. Common Stock share in Q2 2021, an estimated $1K.
  • Clearstead Advisors first reported a position in Vaccinex, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Clearstead Advisors's Vaccinex, Inc. Common Stock position peaked at $1K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q2 2021.

Based on Clearstead Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.